This move is part of a larger €3.5 billion program within the country.
The investment will be allocated to facilities in Vitry-sur-Seine in Val de Marne, Le Trait in Seine-Maritime, and Lyon Gerland in the Rhône region. Its primary objective is to reduce France and the wider EU’s dependence on manufacturing capacity outside the region, thus enhancing supply chain security and resilience.
This initiative aligns with the EU’s concept of health sovereignty, which gained prominence in the aftermath of the COVID-19 pandemic. Health sovereignty focuses on reinforcing pharmaceutical systems and manufacturing capacities for vaccines and medical products, along with improving detection of threats and response mechanisms.
Sanofi’s investment program is expected to create over 500 jobs and bolster France’s ability to oversee the production of essential medicines comprehensively.
The company,…
